Investor / Analyst / MSc Finance / No Advice

Joined December 2019
1,792 Photos and videos
$MRVL Marvell Technology | Meaningfully Raised LT Model as MRVL Stands to Benefit from Secular Tailwinds Across Its DC Product Portfolio; Reiterate Buy
1
7
904
$GWRE Guidewire Software | Business Momentum and Demand Accelerating; Positioned Well In An AI World
3
1,056
$MTN Vail Resorts | U.S. Ski Visitation Tracker: Conditions Remain Challenging in CO/UT; Lowering MTN Estimates
2
648
$COO Cooper Companies | F1Q26 Results: Tug of War - EPS/Margins Lead the Way, Revenue a Bit Light
1
839
$SYK Stryker | AAOS Meetings Highlight Ongoing SYK Focus On Being A Broad, Solution-Oriented Company…Positive For Continued HSD Growth
4
2,119
$CIEN Ciena | Review; Solid F1Q Beat, Healthy F2Q Guide, And Seemingly Conservative FY26 Raise; We Remain Positive
1
314
$CRWD CrowdStrike | A Competitive Moat Becoming an Opportunity Ocean
5
359
$NKE Nike | Read-Throughs from Stifel's All-Star 2026 Athletic Footwear Survey
2
461
$MRVL Marvell Technology Group | F4Q26E Preview: Optical DSP Leadership Anchors Q4 Upside; Custom ASIC Reacceleration to Provide Support
3
6
668
$TREE LendingTree | 4Q Wrap: Raising 2026/'27E EBITDA by 7-8%; Maintain Outperform
1
339
$VIK Viking Holdings | 4Q25 First Take: Demand Remains Healthy; Booking Curves Look Very “Normal” Again; Expect Upside To Our Yield Forecast
1
258
$ONON On Holding | 4Q25 Quick Look
1
3
407
$LIF Life360 | Investing to Start the Year; Growth is 2H Weighted -- Expect 20% MAU Growth and Accelerating PC Growth in FY26
1
1
630
$MDB MongoDB | Good But Not Recent Greatness; LT Thesis Remains Very Much Intact; TP to $330
1
453
$CRDO Credo Technology Group | ZF Optics Rollout Timeline Accelerated by Customer Demand, Even as Persistent AEC Strength Drives NT Outperformance; Buy
7
975
$DKNG DraftKings | Takeaways from Investor Day: 30% L-T Margin Intact; Shifting to All-in-One App Strategy to Drive Leverage
2
341
$PGR The Progressive Corporation | 4Q25 10-K Review: Still Looks Like Decelerating Auto Growth
1
466
25/38 Obesity market model for AIPAC, LatAm, and China
1
149
21/38 Several earlier-stage catalysts in 2026 for incretins and new mechanisms. $PFE $AZN $VKTX
1
1
373
22/38 Developments expected for new mechanisms as well. $WVE $ARWR
2
553